Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AGRONOMICS LIMITED Net Asset Value 2015

Apr 15, 2015

7474_rns_2015-04-15_a3e292a6-754f-4b72-8050-2cb58cec8bef.html

Net Asset Value

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 2025K

Port Erin Biopharma Investments Ltd

15 April 2015

15 April 2015

Port Erin Biopharma Investments Limited

(the "Company")

Net Asset Value calculation to 31 March 2015

Jim Mellon, Chairman, commented: -

"The Net Asset Value ("NAV") calculation for the Company as at closing on 31 March 2015 was 12.32 pence per share, including un-invested cash of £405,665. The portfolio is valued under IFRS at bid price.

Net Assets stand at £2.9 million including Investments of £2.5 million. This follows the successful completion of the tender offer which gave shareholders the opportunity to sell a proportion of their holding back to the Company at their implicit value rather than the historically discounted market price. Our holding in the Magna Biopharma Income Fund now represents 52.2% of the Company's portfolio.

This quarter's NAV represents a decrease of 13.8% from the previous valuation of 14.29 pence per share, which included un-invested cash of £431,744. On this basis, no additional management fee is due to Shellbay Investments Limited.

The reported NAV to 31 March 2015 suffered due to some share price fluctuations in our smaller quoted holdings, all of which have recovered some value in the opening stages of the second quarter. Our principal investment in the Magna Biopharma Income Fund continued to perform strongly, reporting an uplift in share price of 14.7% during the first quarter."

Unaudited to 31 March 2015    £
Fixed Assets
Investments 2,514,425
Current Assets
Sundry Debtors 16,821
Uninvested cash 405,665
Current Liabilities
Creditors: amounts due (79,678)
2,857,233
Capital and Reserves
Share Capital 23
Share Premium 1,890,142
Current year earnings (430,980)
Retained earnings 1,398,048
2,857,233
Shares in Issue 23,195,558
Net Asset Value per share 12.32 pence

Portfolio Details

Investments as at 31 March 2015 Value % of Total Portfolio
Magna Biopharma Income Fund £1,312,807 52.2%
Plethora Solutions Holdings £271,250 10.8%
Summit Corporation £468,616 18.7%
Other quoted holdings £116,859 4.6%
Other unquoted holdings £344,893 13.7%
Total £2,514,425 100.0%

For further information, please contact:

Port Erin Biopharma

Investments Limited
Beaumont Cornish Limited Peterhouse Capital Limited
The Company Nomad Broker
Denham Eke

(+44) (0) 1624 639396
Roland Cornish

(+44) (0) 207 628 3396
Lucy Williams

(+44) (0) 207 469 0936

This information is provided by RNS

The company news service from the London Stock Exchange

END

NAVLLFSSSVISLIE